Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Sirolimus in RUNX1-FPD
NCT06261060Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2024
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sirolimus in Familial Platelet Disorder with Associated Myeloid Malignancy (FPD/AML), sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2024; status: recruiting.
02
Drugs
sirolimus
03
Conditions
Familial Platelet Disorder with Associated Myeloid Malignancy (FPD/AML)
Beyond the preview
Go deeper on NCT06261060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06261060.